Bbva Compass Bancshares Inc. Has $354,000 Position in Edwards Lifesciences Corp (EW)

Bbva Compass Bancshares Inc. boosted its position in Edwards Lifesciences Corp (NYSE:EW) by 16.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,850 shares of the medical research company’s stock after buying an additional 259 shares during the period. Bbva Compass Bancshares Inc.’s holdings in Edwards Lifesciences were worth $354,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Neuberger Berman Group LLC boosted its stake in Edwards Lifesciences by 1.9% during the 3rd quarter. Neuberger Berman Group LLC now owns 693,707 shares of the medical research company’s stock valued at $120,774,000 after purchasing an additional 13,260 shares during the last quarter. Pennsylvania Trust Co boosted its stake in Edwards Lifesciences by 466.0% during the 4th quarter. Pennsylvania Trust Co now owns 10,108 shares of the medical research company’s stock valued at $1,548,000 after purchasing an additional 8,322 shares during the last quarter. Gofen & Glossberg LLC IL boosted its stake in Edwards Lifesciences by 21.1% during the 4th quarter. Gofen & Glossberg LLC IL now owns 2,429 shares of the medical research company’s stock valued at $372,000 after purchasing an additional 424 shares during the last quarter. Dubuque Bank & Trust Co. boosted its stake in Edwards Lifesciences by 70.3% during the 4th quarter. Dubuque Bank & Trust Co. now owns 1,371 shares of the medical research company’s stock valued at $210,000 after purchasing an additional 566 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its stake in Edwards Lifesciences by 276.3% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,505 shares of the medical research company’s stock valued at $230,000 after purchasing an additional 1,105 shares during the last quarter. Hedge funds and other institutional investors own 84.43% of the company’s stock.

Edwards Lifesciences stock opened at $178.89 on Thursday. Edwards Lifesciences Corp has a 52 week low of $134.38 and a 52 week high of $197.86. The company has a current ratio of 3.66, a quick ratio of 2.69 and a debt-to-equity ratio of 0.17. The company has a market cap of $37.20 billion, a price-to-earnings ratio of 38.06, a PEG ratio of 2.28 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, April 23rd. The medical research company reported $1.32 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.23 by $0.09. Edwards Lifesciences had a net margin of 20.03% and a return on equity of 31.16%. The firm had revenue of $993.00 million for the quarter, compared to analysts’ expectations of $989.87 million. During the same quarter last year, the firm earned $1.22 EPS. The company’s quarterly revenue was up 11.0% compared to the same quarter last year. As a group, sell-side analysts expect that Edwards Lifesciences Corp will post 5.28 earnings per share for the current fiscal year.

A number of equities analysts have issued reports on EW shares. Bank of America lifted their price target on Edwards Lifesciences from $190.00 to $215.00 and gave the company a “buy” rating in a research note on Monday, March 18th. JPMorgan Chase & Co. lifted their price target on Edwards Lifesciences from $175.00 to $190.00 and gave the company a “neutral” rating in a research note on Wednesday, March 27th. They noted that the move was a valuation call. Morgan Stanley lifted their price target on Edwards Lifesciences from $180.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, March 18th. Wells Fargo & Co lifted their price target on Edwards Lifesciences from $188.00 to $202.00 and gave the company an “outperform” rating in a research note on Monday, March 18th. Finally, UBS Group lifted their price target on Edwards Lifesciences from $175.00 to $180.00 and gave the company a “neutral” rating in a research note on Tuesday, March 12th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have issued a buy rating to the stock. Edwards Lifesciences currently has a consensus rating of “Buy” and a consensus price target of $187.00.

In related news, VP Robert W.A. Sellers sold 821 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $175.36, for a total value of $143,970.56. Following the sale, the vice president now owns 14,176 shares of the company’s stock, valued at approximately $2,485,903.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Catherine M. Szyman sold 1,474 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $177.92, for a total transaction of $262,254.08. Following the completion of the sale, the vice president now directly owns 21,396 shares in the company, valued at approximately $3,806,776.32. The disclosure for this sale can be found here. Insiders sold a total of 148,411 shares of company stock worth $26,189,586 in the last ninety days. 1.63% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://transcriptdaily.com/2019/05/16/bbva-compass-bancshares-inc-has-354000-position-in-edwards-lifesciences-corp-ew.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Article: Benefits of owning preferred stock

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.